Evaluation of Immunoprotective Activity of Septilin against Cyclosporine A induced Immune Suppression

Immunoprotective activity of Septilin evaluated against Cyclosporine A induced immunosuppression in wistar albino rats. An equivalent of 100mg of Septilin tablet extract administered as an oral dose and its Immunoprotective activity assessed by determining of host resistance against E.coli, determining hematological parameters (Total Leukocyte Count), determining in vivo phagocytic test by carbon clearance, determining humoral response (by measuring antibody titre) and cell mediated immunity (by measuring foot pad thickness). The present study suggests that Septilin significantly protected the animals by increasing the immunoprotective activity in immune compromised conditions. In Septilin treated, immunosuppressed rats, there was 33.3% mortality against 100% mortality in immunosuppressed rats after 48hrs of infection. 16.6% mortality was observed in Septilin treated rats against 66.6% in immunosuppressed rats after 24hrs of infection. Furthermore, Septilin treatment raised the TLC significantly (P<0.01) when compared with control immunosuppressed rats. It was also found that Septilin treatment potentiated the phagocytic activity in immunosuppressed animals. The antibody titre determination study suggested that Septilin enhances both primary and secondary responses in rats immunized with BSA. In normal rats, Septilin increased the primary antibody titre values by 2.4 times and the secondary antibody titre values by 1.56 times. In immune suppressed rats, Septilin increased the primary antibody titre values by 2.5 times and secondary antibody titre values by 1.81 times. Septilin also showed the protective activity against impaired DTH conditions.